Targeted- and timed-releasing nanotherapeutics against leukemia stem cells

针对白血病干细胞的靶向和定时释放纳米疗法

基本信息

  • 批准号:
    9260776
  • 负责人:
  • 金额:
    $ 35.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-15 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The goal of this project is to develop nanotherapeutics that can specifically deliver the chemotherapeutic drug daunorubicin into acute myeloid leukemia (AML) stem cells (targeted delivery) and release the drug inside the cells (timed release) in order to eradicate this cell population. Current chemotherapy for AML is disappointing in that it can cure only a minority of AML patients and is associated with severe toxicity and significant mortality even with intensive inpatient monitoring and supportive care. Leukemia stem cells (LSC) are relatively resistant to the conventional chemotherapy and can subsequently produce more leukemia cells to cause disease recurrence. In order to cure leukemia, LSC must be eradicated. The C-type lectin-like molecule-1 (CLL-1) is a cell surface protein that is specifically expressed on most AML LSC, but not on normal hematopoietic stem cells. We have developed a peptide that specifically targets CLL1. When this peptide is covalently attached to a nanometer-scale micellar drug formulation, the resulted targeting nanoparticles, called micelles, can specifically deliver the drug load into cells expressing CLL1, including clinical leukemia specimens. The drug-loaded, CLL1-targeting micelles are stable in blood, and can potentially improve therapy against AML by (1) delivering a high local concentration of daunorubicin specifically into LSC, overwhelming the resistant mechanisms and eradicating LSC; (2) killing leukemic cells throughout the body with the release of daunorubicin from the micelles and LSC into circulation; (3) decreasing therapy-induced toxicity and mortality owing to the sequestration of the drug inside the micelles; and (4) allowing administration of high-dose daunorubicin with reduced toxicity through formulation of daunorubicin into micelles.
 描述(由申请人提供):该项目的目标是开发纳米治疗剂,其可以特异性地将化疗药物柔红霉素递送到急性髓性白血病(AML)干细胞中(靶向递送),并在细胞内释放药物(定时释放),以根除该细胞群。目前AML的化疗令人失望,因为它只能治愈少数AML患者,即使在强化住院监测和支持性护理下,也与严重毒性和显著死亡率相关。白血病干细胞(Leukemia stem cells,LSC)对常规化疗具有较强的抵抗力,可产生更多的白血病细胞,导致疾病复发。为了治愈白血病,必须根除LSC。C型凝集素样分子-1(CLL-1)是一种细胞表面蛋白,在大多数AML LSC上特异性表达,但在正常造血干细胞上不表达。我们开发了一种特异性靶向CLL 1的肽。当这种肽共价连接到纳米级胶束药物制剂时,所产生的靶向纳米颗粒(称为胶束)可以特异性地将药物负载递送到表达CLL 1的细胞中,包括临床白血病标本。载药的CLL 1靶向胶束在血液中是稳定的,并且可以通过(1)将高局部浓度的柔红霉素特异性递送到LSC中,压倒耐药机制并根除LSC;(2)通过柔红霉素从胶束和LSC释放到循环中杀死全身的白血病细胞;(3)由于药物在胶束内的隔离,降低了治疗诱导的毒性和死亡率;和(4)通过将柔红霉素配制成胶束,允许以降低的毒性施用高剂量柔红霉素。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHONG-XIAN PAN其他文献

CHONG-XIAN PAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHONG-XIAN PAN', 18)}}的其他基金

BCCMA: Translational research to improve the care of advanced bladder cancer
BCCMA:改善晚期膀胱癌护理的转化研究
  • 批准号:
    10588312
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
癌症靶向胶束治疗非肌浸润性膀胱癌的 I 期试验
  • 批准号:
    10426035
  • 财政年份:
    2020
  • 资助金额:
    $ 35.91万
  • 项目类别:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
癌症靶向胶束治疗非肌浸润性膀胱癌的 I 期试验
  • 批准号:
    10578717
  • 财政年份:
    2020
  • 资助金额:
    $ 35.91万
  • 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
  • 批准号:
    10158416
  • 财政年份:
    2018
  • 资助金额:
    $ 35.91万
  • 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
  • 批准号:
    9898243
  • 财政年份:
    2018
  • 资助金额:
    $ 35.91万
  • 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
  • 批准号:
    10085104
  • 财政年份:
    2018
  • 资助金额:
    $ 35.91万
  • 项目类别:
Targeted-and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向定时释放纳米疗法
  • 批准号:
    10162055
  • 财政年份:
    2015
  • 资助金额:
    $ 35.91万
  • 项目类别:
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向和定时释放纳米疗法
  • 批准号:
    9454297
  • 财政年份:
    2015
  • 资助金额:
    $ 35.91万
  • 项目类别:
Development of targeting nanotherapeutics against bladder cancer
膀胱癌靶向纳米疗法的开发
  • 批准号:
    8442030
  • 财政年份:
    2013
  • 资助金额:
    $ 35.91万
  • 项目类别:
Development of targeting nanotherapeutics against bladder cancer
膀胱癌靶向纳米疗法的开发
  • 批准号:
    9275369
  • 财政年份:
    2013
  • 资助金额:
    $ 35.91万
  • 项目类别:

相似海外基金

The Role of Arginine Transport on Pancreatic Alpha Cell Proliferation and Function
精氨酸转运对胰腺α细胞增殖和功能的作用
  • 批准号:
    10678248
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Alpha cell-derived Extracellular Vesicles and Maternal Insulin Production
α细胞来源的细胞外囊泡和母体胰岛素的产生
  • 批准号:
    10681939
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
  • 批准号:
    10427574
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Regulation of alpha-cell glucagon secretion by mitochondrial anaplerosis-cataplerosis
线粒体回补-回补对α细胞胰高血糖素分泌的调节
  • 批准号:
    10607392
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Arginine regulation of alpha cell proliferation and function
精氨酸调节α细胞增殖和功能
  • 批准号:
    10609909
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
  • 批准号:
    10675646
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Elucidating alpha cell defects in human type 1 diabetes using precision cut pancreas slice-on-a-chip coupled with high spatio-temporal microscopy
使用精密切割的胰腺切片结合高时空显微镜阐明人类 1 型糖尿病的 α 细胞缺陷
  • 批准号:
    457552
  • 财政年份:
    2021
  • 资助金额:
    $ 35.91万
  • 项目类别:
    Studentship Programs
Defining alpha-cell proglucagon processing for type 2 diabetes treatment
定义 2 型糖尿病治疗的 α 细胞胰高血糖素原加工过程
  • 批准号:
    10331361
  • 财政年份:
    2020
  • 资助金额:
    $ 35.91万
  • 项目类别:
In vivo systems to discover mechanisms regulating human islet alpha cell function
体内系统发现调节人类胰岛α细胞功能的机制
  • 批准号:
    10623306
  • 财政年份:
    2020
  • 资助金额:
    $ 35.91万
  • 项目类别:
Defining alpha-cell PC1/3 expression regulation for type 2 diabetes
定义 2 型糖尿病的 α 细胞 PC1/3 表达调控
  • 批准号:
    10376866
  • 财政年份:
    2020
  • 资助金额:
    $ 35.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了